XML 99 R67.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

DIVESTITURES - Narrative (Details) divestiture in Millions, $ in Millions |  |  |  |  |  | 7 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | ---
Dec. 20, 2017 USD ($) | Nov. 09, 2017 USD ($) | Sep. 29, 2017 USD ($) | Jun. 28, 2017 USD ($) | Mar. 03, 2017 USD ($) | Nov. 08, 2017 USD ($) | Dec. 31, 2019 USD ($) country product | Dec. 31, 2018 USD ($) divestiture | Dec. 31, 2017 USD ($)
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Number of material divestitures | divestiture |  |  |  |  |  |  |  | 0 |
Impairment write-down |  |  |  |  |  |  | $ 8 |  |
Number of countries in which entity operates (more than) | country |  |  |  |  |  |  | 100 |  |
Impairment of finite-lived intangible assets |  |  |  |  |  |  | $ 5 |  |
Held For Sale |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Impairment write-down |  |  |  |  |  |  |  | $ 5 | $ 114
Certain Products For Disposal, September 2019 | Held For Sale |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Disposal group, revenue |  |  |  |  |  |  | 14 | 19 |
Impairment write-down |  |  |  |  |  |  | 8 |  |
CeraVe, AcneFree, AMBI Skincare Brand |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Gain (loss) on sale of business |  |  |  |  |  |  | 0 | 0 | 309
CeraVe, AcneFree, AMBI Skincare Brand | Held For Sale |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Net cash proceeds |  |  |  |  | $ 1,300 |  |  |  |
Gain (loss) on sale of business |  |  |  |  |  |  |  |  | 309
Dendreon |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Gain (loss) on sale of business |  |  |  |  |  |  | 0 | 0 | 97
Dendreon | Held For Sale |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Net cash proceeds |  |  |  | $ 845 |  |  |  |  |
Gain (loss) on sale of business |  |  |  |  |  |  |  |  | 97
iNova |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Gain (loss) on sale of business |  |  |  |  |  |  | $ 0 | 0 | 309
iNova | Held For Sale |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Net cash proceeds |  |  | $ 938 |  |  |  |  |  |
Gain (loss) on sale of business |  |  |  |  |  |  |  |  | 309
Number of countries in which entity operates (more than) | country |  |  |  |  |  |  | 15 |  |
Obagi Medical Products, Inc. | Held For Sale |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Impairment of finite-lived intangible assets |  |  |  |  |  | $ 103 |  |  |
Obagi Medical Products, Inc. | Disposal Group, Disposed of by Sale, Not Discontinued Operations |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Net cash proceeds |  | $ 190 |  |  |  |  |  |  |
Gain (loss) on sale of business |  |  |  |  |  |  |  |  | (13)
Sprout |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Gain (loss) on sale of business |  |  |  |  |  |  | $ 0 | $ 0 | (98)
Loan term | 5 years |  |  |  |  |  |  |  |
Related party loan | $ 25 |  |  |  |  |  |  |  |
Sprout | Minimum |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Purchase obligation (no less than) | $ 200 |  |  |  |  |  |  |  |
Sprout | Held For Sale |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Impairment write-down |  |  |  |  |  |  |  |  | 351
Sprout | Disposal Group, Disposed of by Sale, Not Discontinued Operations |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Gain (loss) on sale of business |  |  |  |  |  |  |  |  | $ (98)
Royalty percentage | 6.00% |  |  |  |  |  |  |  |
Diversified Products | Certain Products For Disposal, September 2019 | Held For Sale |  |  |  |  |  |  |  |  |
Asset acquisitions and disposition |  |  |  |  |  |  |  |  |
Number of products for disposal | product |  |  |  |  |  |  | 1 |  |

X
- Definition Disposal Group, Including Discontinued Operation, Consideration, Royalty Percentage + References No definition available. + Details
Name: | bhc_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyPercentage
Namespace Prefix: | bhc_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disposal Group, Number Of Products For Disposal + References No definition available. + Details
Name: | bhc_DisposalGroupNumberOfProductsForDisposal
Namespace Prefix: | bhc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loans And Leases Receivable, Term + References No definition available. + Details
Name: | bhc_LoansAndLeasesReceivableTerm
Namespace Prefix: | bhc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Divestitures + References No definition available. + Details
Name: | bhc_NumberOfDivestitures
Namespace Prefix: | bhc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5B -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760 + Details
Name: | us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684 + Details
Name: | us-gaap_GainLossOnSaleOfBusiness
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228 + Details
Name: | us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.7(e)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_LoansAndLeasesReceivableRelatedParties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The number of countries in which the entity operates as of balance sheet date. + References No definition available. + Details
Name: | us-gaap_NumberOfCountriesInWhichEntityOperates
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromDivestitureOfBusinesses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + References No definition available. + Details
Name: | us-gaap_PurchaseObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CeraVeAcneFreeAMBISkincareBrandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_DendreonPharmaceuticalsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_INovaPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_ObagiMedicalProductsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_SproutPharmaceuticalsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_DiversifiedProductsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |